Ethex Hydromorphone Recall: Latest in Series of Drugs Sold With Oversized Tablets

Another major Ethex recall was issued on December 23, 2008, this time involving generic Hydromorphone HCI tablets which may be oversized, posing a potential risk of overdose and other serious injury.

This is the fifth recall issued this year by Ethex Corp. due to oversized tablets of generic drugs, leading their parent company, KV Pharmaceutical, to suspend shipments of all drug products they manufacture in tablet form.

The Ethex Hydromorphone recall applies to one lot of 2 mg tablets with Lot #90219, NDC#58177-0620-04 and an expiration date of 03/2010. The drug is labeled under the “Ethex” name and packaged in bottles with 100 round and blue tablets, containing a “2” on one side an “E” on the other side.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

It is possible that there may be oversized Hydromorphone tablets in this lot, which contain more of the active pharmaceutical ingredient than is appropriate.

Hydromophone is a prescription drug used for pain management. Receiving higher than expected doses could increase the risk of serious and potentially life-threatening side effects, such as difficulty breathing, respiratory depression, low blood pressure or sedation.

So far this year, under five separate recalls, at least 13 different variations of generic drugs manufactured under the Ethex name have been recalled due to potential oversized tablets being commercially released.

On June 10, 2008, the recalls started with one lot of Ethex Sulfate 60mg Extended Release tablets. A few days later, Ethex expanded their Morphine recall to add 64 more lots of 30mg and 60mg Morphine Sulfate ER tablets.

Morphine is an opioid which can lead to a fatal overdose if too much of the medication is received, and a number of potential Morphine overdose lawsuits are currently being investigated against Ethex for allowing oversized tablets to leave their factory.

On October 15, 2008, Ethex issued a Dextroamphetamine Sulfate recall for three lots of their 5mg tablets. The following month, additional Dextroamphetamine Sulfate 10mg tablets were recalled along with additional Morphine and other generic drugs, including Propafenone HCI tablets and Isosorbide Mononitrate ER tablets.

KV Pharmaceutical, which is the parent company of Ethex Corp., advised the FDA on December 19, 2008 that they are suspending shipment of all FDA-approved drug products in tablet form. This will allow the drug maker to address manufacturing issues which have been plaguing the company all year, and improve their quality systems to prevent tablets with incorrect doses from being commercially released in the future.

As a result of the suspension of KV Pharmaceutical and Ethex tablet drugs, shipments will be discontinued for Benazepril HCl Tablets, Buspirone HCl Tablets, Dextroaphetamine Sulfate Tablets, Doxazosin Mesylate Tablets, Hydromorphone HCl Immediate Release Tablets, Isosorbide Mononitrate Extended-Release Tablets, Metoprolol Succinate Extended Release Tablets, Morphine Sulfate Extended Release Tablets, Ondansetron Orally Disintegrating Tablets, Oxycodone HCl Tablets, Potassium Chloride 20 mEq Extended-Release Tablets and Propafenone HCl Tablets.

2 Comments

  • MicroK Extencaps, Oxycodone and Morphine Among Dozens of Drug Recalls : AboutLawsuits.comJanuary 29, 2009 at 4:55 pm

    [...] FDA inspections have uncovered a number of violations of Good Manufacturing Practices, causing KV Pharmaceuticals to notify the FDA on December 19, 2008 that they were suspending shipment of all drug products in tablet form. [...]

  • Following Morphine Recall and Other Generic Drug Problems, KV Pharma Suspends All Shipments : AboutLawsuits.comJanuary 27, 2009 at 4:47 pm

    [...] taken following a series of manufacturing problems over the past year, which has led to several recalls of Morphine Sulphate and other generic drugs which were sold with more of the active drug than they were supposed to [...]

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted today)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.

Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL
Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL (Posted yesterday)

In advance of a a conference this week, lawyers report that progress is being made to prepare a group of federal Gardasil vaccine lawsuits for early test trials, to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.